Merck MRK
NYSE MRK
$146.77 -0.36 (-0.24%)
At close: Sep 18, 2026 · 4:00 PM EDT

Merck (MRK) Amortizatization of Intangibles (2020 - 2026)

Merck's (MRK) quarterly Amortizatization of Intangibles came in at $984.0 million in Q2 2026, up 63.73% year-over-year from $601.0 million in Q2 2025, and up 5.69% quarter-over-quarter from $931.0 million in Q1 2026.

Analysis

Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends

Merck (MRK) has reported Amortizatization of Intangibles for 7 consecutive years, with $984.0 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Amortizatization of Intangibles rose 63.73% year-over-year to $984.0 million in Q2 2026; TTM through Jun 2026 was $3.5 billion, a 40.1% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, up 16.62% from the prior year.
  • Amortizatization of Intangibles was $984.0 million for Q2 2026 at Merck, up from $931.0 million in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $984.0 million in Q2 2026 and troughed at $460.0 million in Q3 2022.
  • A 5-year average of $624.0 million and a median of $599.0 million in 2025 frame the typical range for Amortizatization of Intangibles.
  • Across the five-year window, Amortizatization of Intangibles dropped 22.32% in 2023 and surged 63.73% in 2026, its largest moves.
  • Over 5 years, Amortizatization of Intangibles stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then soared by 46.1% to $675.0 million in 2024, then jumped by 44.15% to $973.0 million in 2025, then climbed by 1.13% to $984.0 million in 2026.
  • The last three Amortizatization of Intangibles figures came in at $984.0 million (Q2 2026), $931.0 million (Q1 2026), and $973.0 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn -
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn 984.00 Mn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn -
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn -
8 Revolution Medicines 40.91 Bn 40.91 Bn - 4.33 Mn
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 984.00 Mn
Mar 31, 2026 931.00 Mn
Dec 31, 2025 973.00 Mn
Sep 30, 2025 623.00 Mn
Jun 30, 2025 601.00 Mn
Mar 31, 2025 597.00 Mn
Dec 31, 2024 675.00 Mn
Sep 30, 2024 633.00 Mn
Jun 30, 2024 614.00 Mn
Mar 31, 2024 473.00 Mn
Dec 31, 2023 462.00 Mn
Sep 30, 2023 562.00 Mn
Jun 30, 2023 477.00 Mn
Mar 31, 2023 543.00 Mn
Dec 31, 2022 462.00 Mn
Sep 30, 2022 460.00 Mn
Jun 30, 2022 463.00 Mn
Mar 31, 2022 699.00 Mn
Dec 31, 2021 405.00 Mn
Sep 30, 2021 360.00 Mn